Literature DB >> 10594395

Onset of action during on-demand treatment with maalox suspension or low-dose ranitidine for heartburn.

R A Faaij1, J M Van Gerven, I Jolivet-Landreau, A A Masclee, E M Vendrig, R C Schoemaker, L D Jacobs, A F Cohen.   

Abstract

AIM: To compare the onset of action of the local antacid Maalox and the systemic H2-antagonist ranitidine, during 'on demand' ambulant treatment of a single heartburn episode, using a randomized, parallel group, double-blind, double-dummy design.
METHODS: Subjects with self-perceived heartburn without known gastrointestinal disease or interfering treatments were selected with questionnaires. The study was performed unsupervised, whenever heartburn required medication. An electronic patient diary gave instructions when to take study medication, and provided visual analogue scales and five-item relief ratings for heartburn, at frequent time intervals activated by an alarm-clock.
RESULTS: After a study of the natural history of heartburn and the feasibility of the study procedures in 23 patients, 49 subjects took Maalox and 45 ranitidine. Half of these experienced meaningful heartburn relief within 19 min after Maalox, and within 70 min after ranitidine. One hour after intake, the average heartburn relief score was 3.43 in the Maalox group and 3.04 in the ranitidine group (3 means 'slight improvement' and 4 'strong improvement'). Heartburn was similar in both groups after 3 h.
CONCLUSIONS: Maalox provides faster relief of heartburn than ranitidine. Heartburn can be assessed frequently and reliably under ambulant conditions using an electronic patient diary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594395     DOI: 10.1046/j.1365-2036.1999.00654.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

2.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

3.  A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

Authors:  Abdallah A Kobeissy; Jana G Hashash; Faek R Jamali; Assaad M Skoury; Reham Haddad; Sarah El-Samad; Rami Ladki; Rola Aswad; Assaad M Soweid
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

Review 4.  On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations.

Authors:  John M Inadomi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation?

Authors:  Stacy B Menees; Amanda Guentner; Samuel W Chey; Richard Saad; William D Chey
Journal:  Am J Gastroenterol       Date:  2015-06-09       Impact factor: 10.864

6.  Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders : A noninterventional study with Iberogast®.

Authors:  Richard Raedsch; Bettina Vinson; Bertram Ottillinger; Gerald Holtmann
Journal:  Wien Med Wochenschr       Date:  2017-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.